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INTRODUCTION 
 
                The concept of the metabolic syndrome has existed for at least 
80 years.1 Initially constellation of risk factors like hypertension, 
hyperglycemia, and gout were included as a component of metabolic 
cardiovascular risk factor by Kylin in 1920.2 Later, in 1947, Vague found 
that upper body (android) adiposity was associated with metabolic 
abnormalities associated with type 2 diabetes and cardiovascular disease.3 
            
 Later constellation of metabolic abnormalities includes glucose 
intolerance (type 2 diabetes, impaired glucose tolerance, or impaired 
fasting glycaemia), insulin resistance, central obesity, dyslipidaemia, 
and hypertension as a component of metabolic syndrome, which is also 
known as syndrome X,4 or Insulin resistance syndrome.5  
 
Subsequently, the National Cholesterol Education Program 
Adult Treatment Panel 3 have formulated definition of metabolic 
syndrome includes the essential components-glucose intolerance, 
obesity, hypertension, and dyslipidaemia which provide a tool for 
clinicians researchers. 6 
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Both metabolic syndrome and diabetes are associated with 
increased prevalence of cardiovascular disease when they co-exist. We 
examined the role of metabolic syndrome alone without diabetes as a 
risk factor for cardiovascular disease in our study population. 
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THE OBJECTIVES OF THE STUDY 
 
1. To estimate the prevalence of metabolic syndrome in the elderly 
 
2. To estimate the prevalence of vascular diseases (coronary heart 
disease/ stroke/ peripheral arterial disease) in elderly with the 
metabolic syndrome with or without diabetes when compared with 
subjects without metabolic syndrome. 
 
3. To estimate whether metabolic syndrome alone without diabetes is 
an independent risk factor for vascular diseases in elderly. 
 
4. To find the strength of correlation of metabolic syndrome 
components with vascular diseases. 
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REVIEW OF LITERATURE 
 
METABOLIC SYNDROME  
 
       The concept of metabolic syndrome is the most significant 
development in the management of CV disease for the past two 
decades. There is clearly an association of insulin resistance (IR) and 
hyperinsulinemia with metabolic risk factors that are involved in the 
etiology of atherosclerotic disease. 
 
  IR syndrome provides an important concept for screening and 
aggressively treating patients for multiple CV risk factors with a 
variety of drugs some of which are efficacious in the treatment of 
insulin resistance itself. 
 
  Insulin resistance represents a major underlying abnormality 
driving cardiovascular disease, the major cause of morbidity and 
mortality globally. Previously physicians often treated co-existing 
diabetes, hypertension or dyslipidemia as separate diseases without 
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considering the impact of treatment for one on the other. Gerald 
Reaven drew attention to a constellation of features associated with 
coronary heart disease.7 
 
Currently, insulin resistance is defined clinically as the inability 
of a known quantity of exogenous or endogenous insulin to increase 
glucose uptake and utilization in an individual as such as it does in a 
normal population. 
 
Components of metabolic syndrome: 
Resistance to insulin-stimulated glucose uptake  
Glucose intolerance  
Hyperinsulinemia 
Increased VLDL triglyceride  
Decreased HDL cholesterol  
Hypertension  
Central obesity  
Microalbuminuria  
High plasminogen activator inhibitor - 1  
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Hyperleptinemia 
Hyperuricemia 
 
Insulin resistance and Diabetes 
 
Genes and the environment play a role in the development of 
type 2 diabetes. The early prediabetic phase begins in young adulthood 
and can be identified as insulin resistance in peripheral tissues. 
Initially, insulin levels are elevated in response to the resistance, but as 
glucose desensitization develops, insulin secretion decreases. This 
eventually leads to clinical non-insulin— dependent diabetes.  
 
Both the insulin resistance and the decreased insulin secretion 
are genetically programmed. This program is modified by a variety of 
environmental factors, especially diet and activity.8 overt diabetes will 
develop when insulin cannot be increased to overcome insulin 
resistance. In comparison with thin patients, many obese patients 
without diabetes produce 5 to 8 times more insulin (500 U/day) to 
overcome insulin resistance. 
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Insulin resistance and Obesity 
 
Several large studies provide convincing evidence of the link 
between obesity per se and coronary heart disease. More recently, in the 
analysis of the Nurses’ study, a body mass index of 25— 28.9 was 
associated with a twofold increase in CV disease; the risk rose to almost 
fourfold once the BMI exceeded 29.9 Strong evidence now links obesity 
with left ventricular hypertrophy, hypertension, alterations in haemostatic 
factors, and alteration in lipid profiles.10 Visceral adiposity plays a greater 
role in the development of diabetes, IGT, and atherosclerosis than 
generalized obesity. Regional adiposity is closely associated with 
morbidity and mortality than general obesity. 
 
San Antonio Heart Study 
 
A combination of three or more risk factors for CHD in the same 
cardiac patient was more prevalent than either one factor alone or two 
factors in combination. Hyperinsulinemia might provide the common 
etiologic link. This forms one of the epidemiological evidence of 
metabolic syndrome and coronary artery disease 
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Clinical diagnosis of metabolic syndrome 
 
Risk Factor  Defining Level  
Abdominal Obesity (waist circumference)   
Men  >102 cm (40 inch)  
Women  > 88 cm (32 inch)  
Triglycerides  ≥150mg/dl (1.7mmol/L)  
HDL cholesterol 
                       Men  
< 40 mg/dl (1.0 mmol/L)  
HDL cholesterol 
                      Women  
< 50 mg/dl (1.1 mmol/L) 
Blood Pressure  ≥130 / 85 mmHg  
Fasting Plasma glucose  ≥110 mg/dl  
Diagnosis is established when >3 of these 
risk factors are present 
 
 
 
International Association for the study of obesity and the 
International Obesity Task Force redefined overweight as BMI >23 
and obesity as BMI >25 in Asians. Central obesity was defined as >80 
cm for women and >90 for men.11 
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METABOLIC SYNDROME AND DIABETES 
 
Today, India has a primary position in the global diabetes 
epidemiology map as it is the home of nearly 33 million diabetic 
subjects which is the highest number in the world. This is both, due to 
a rising prevalence of the disease and the large population in the 
country. Initially study conducted by the ICMR showed prevalence 
was 3%. But there was gradual increase in prevalence of diabetes.  
 
A recent study in Southern India showed that the prevalence had 
increased from 2.1% to 6.3%12.This increase in mainly contributed by 
the urban population which has undergone significant changes in the 
lifestyle pattern. 
 
The preclinical stages of diabetes, impaired fasting glucose 
(IFG) and impaired glucose tolerance (IGT) are also steadily 
increasing. It indicates the potential for a future increase in diabetes as 
these conditions deteriorate when the environmental factors are 
adverse.  
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The major risk factors associated with diabetes are positive 
family history, age, obesity, especially upper body adiposity, physical 
inactivity and insulin resistance. Urban environment increases obesity, 
physical inactivity and causes unhealthy diet habits all of which lead to 
increased insulin resistance. Indians have a racial predisposition and a 
high familial aggregation of diabetes, effect of which is precipitated by 
the above environmental factor. 
 
A series of studies have indicated that Indians have several 
peculiar features such as low risk thresholds for susceptibility for 
diabetes. These include a young age at onset, low normal range for 
body adiposity < 23.0 kg/m2, presence of central adiposity despite 
having normal and high insulin resistance.  
 
Indian have a high genetic susceptibility for diabetes and the 
above factors act adversely in such individuals. Because of the above 
facts screening for the metabolic syndrome is essential in preventing 
both diabetes and its complication.  
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Dysglycemia is commonly associated with the metabolic 
syndrome, characterized by the clustering of CHD risk factors like 
obesity, hypertension and dyslipidaemia in a single individual. These 
risk factors increase the risk of development of type 2 diabetes and 
also have a multiplicative effect on the risk for development of CHD. 
Recognition and treatment of the metabolic syndrome would help in 
prevention of type 2 diabetes and CHD. 
 
The normal values proposed by the American diabetes 
association is as follows 
 
 Category Fasting Plasma Glucose (mg/dl) 
2hr Post Glucose Plasma glucose 
(mg/dl) 
Normal < 110 < 140 
IFG 110 - 125 < 140 
IGT < 110 140-199 
Diabetes > 126 > 200 
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Impaired fasting glucose 
 
The IFG denotes an abnormally high fasting glucose 
concentration which falls short of diagnosis of diabetes (plasma 
glucose 110-125 mg/dl.13 The defects in insulin action in glucose 
metabolism include deficiencies in the ability of the hormone to 
suppress glucose production by the liver and kidney, and to mediate 
glucose uptake and metabolism in insulin sensitive tissues (i.e., muscle 
and adipose tissue).  
 
The relation between impaired fasting glucose or impaired 
glucose tolerance and insulin resistance is well supported by human, 
non-human primate, and rodent studies to compensate for defects in 
insulin action, insulin secretion and/or clearance must be modified to 
sustain euglycaemia. If this compensation fails, a defect in insulin 
secretion predominates. 
  
Insulin resistance in pancreatic islet beta cells implies that, 
signals that generate glucose-dependent insulin secretion have been 
adversely modified, and fatty acids are prime candidates. Although  
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free fatty acids can stimulate insulin secretion; increasing and 
prolonged exposure to excessive concentrations results in fall in 
insulin secretion.14 The mechanism for this alteration has been 
attributed to lipotoxicity through several potential different 
mechanisms.15 
 
IGT and IFG are not synonymous in terms of pathophysiology 
and in the development of the long term complications. The term 
prediabetes is a practical and convenient term for impaired fasting 
glucose and impaired glucose tolerance, which places individuals at 
risk of developing diabetes and its complications. Both IGT and IFG 
appear well before type 2 diabetes is diagnosed thereby presenting an 
opportunity for intervention to reduce the future burden of diabetes.  
 
Not all individuals with prediabetes will necessarily progress to 
diabetes. A significant proportion of people who are diagnosed with 
IGT will revert to normoglycemia. IFG and IGT are associated with 
the metabolic syndrome which includes obesity, dyslipidaemia of the 
high triglyceride and/ or low HDL cholesterol and hypertension.  
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Identifying people with prediabetes particularly in the context of 
the metabolic syndrome indicates those who would benefit from 
cardiovascular risk modification. While people with isolated IFG/IGT 
do not have risk for micro vascular disease, they have a higher risk for 
the development of diabetes and cardiovascular disease. 
  
IGT is more strongly associated with CHD outcomes. However, 
individuals identified as having both IFG and IGT are at higher risk for 
diabetes as well as CHD. Lifestyle interventions have been shown to 
be highly effective in delaying or preventing the onset of diabetes in 
people with IGT. 
 
In the NHANES III data, it was found that impaired fasting 
glucose had twice the prevalence of CHD compared with normal 
glucose levels and diabetes had three times the prevalence.16 
 
In a recent study from North India the prevalence of IFG was 
found to be 11.7% in the population. Individuals with IFG had a 
clustering of cardiovascular risk factors and the prevalence of the 
Metabolic Syndrome as per NCEP ATP III criteria was 61% in this 
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group with IFG compared with 16% in those with normoglycemia 
(p<0.001).17  
 
The major risk factors (cigarette smoking, hypertension and 
dyslipidaemia) contribute to the cardiovascular risk in diabetic 
populations. For each CHD risk factor analyzed in the MRFIT trial the 
risk of CHD was approximately three-fold greater in the diabetic than 
in the non-diabetic population.18 
 
METABOLIC SYNDROME AND DYSLIPIDAEMIA  
 
NATIONAL CHOLESTEROL EDUCATION GUIDLINE classify the 
lipids and their normal values are 
 
Classification of plasma lipids 
 
Total cholesterol (mg/dl) 
 < 200  - Desirable 
 200 – 239 - Borderline high 
 ≥ 240  - High 
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HDL cholesterol (mg/dl) 
 < 40   - Low (<50 for Females) 
 > 60   - High  
 
LDL cholesterol (mg/dl) 
 < 100            - Optimal 
 100 – 129  - Near optimal 
 130 – 259  - Borderline high 
 160 – 189   - High 
  ≥ 190  - Very high 
 
Triglycerides (mg/dl) 
 < 150   - Normal 
 150 – 199  - Borderline high 
 200 – 499  - High 
  ≥ 500  - Very high 
 
In general, with increases in free fatty acid flux to the liver, 
increased production of apo B containing triglyceride rich VLDL 
occurs.19 The effect of insulin on this process is complex. In the setting 
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of insulin resistance, increased flux of free fatty acids to the liver 
increases hepatic triglyceride synthesis; but under physiological 
conditions, insulin inhibit VLDL secretion into systemic circulation.20 
This response in part is an effect of insulin on the degradation of apo 
B. Yet insulin is also lipogenic, increasing transcription of many genes 
related to triglyceride biosynthesis.  
 
Additionally, insulin resistance could also reduce the 
concentration of lipoprotein lipase in peripheral tissues (i.e. in adipose 
tissue more than muscle).21 This alteration in lipoprotein lipase, 
however contribute less to the hypertriglyceridemia than does the 
overproduction of VLDL. Nevertheless hypertriglyceridemia is an 
excellent reflection of insulin resistant condition and is an important 
diagnostic criterion for metabolic syndrome. 
 
The other major lipoprotein disturbance in the metabolic 
syndrome is a reduction in HDL cholesterol. This reduction is a 
consequence of changes in HDL composition and metabolism. In the 
presence of hypertriglyceridemia, a decrease in the cholesterol content 
of HDL results from decreases in the cholesteryl ester content of the  
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lipoprotein core with variable increases in triglyceride making the 
particle small and dense, a function in part of cholesteryl ester transfer 
protein.22 This change in lipoprotein composition also results in an 
increased clearance of HDL from the circulation.23 The relation of 
these changes in HDL to insulin resistance is probably indirect, arising 
in concert with the changes in triglyceride-rich lipoprotein metabolism. 
 
In addition to HDL, the composition of LDL is also modified in 
similar way. In fact, with fasting serum triglycerides > 2 mmol/l, 
almost all patients have a predominance of small dense LDL.24 This 
change in LDL composition is attributable to relative depletion of 
unesterified and esterified cholesterol, and phospholipids with either 
no change or an increase in LDL triglyceride.25  
 
Small dense LDL is more atherogenic than buoyant LDL 
because it is more toxic to the endothelium; it is more able to transit 
through the endothelial basement membrane; it adhere well to 
glycosaminoglycans; it has increased susceptibility to oxidation; it is 
more selectively bound to scavenger receptors in macrophages.26  
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In some studies this alteration is an independent risk factor for 
cardiovascular disease.27 However most of the time it is related to 
concomitant changes in other lipoproteins and other risk factors.28 
 
Dyslipidaemia is present in over 50% of the diabetic population 
and constitutes a major risk factor for CHD, particularly as it persists 
despite the treatment of hyperglycemia. Diabetic dyslipidaemia is 
characterized by moderate hypertriglyceridemia and low levels of HDL 
cholesterol. The levels of total cholesterol and LDL cholesterol are 
similar to that in the non-diabetic population. However, the 
distribution of LDL particles in diabetic subjects is shifted towards 
smaller denser particles that are thought to be particularly atherogenic. 
  
Hypertriglyceridemia is a major determinant of the distribution 
of LDL particles - the higher the fasting triglyceride level, the greater 
the preponderance of the small dense LDL in the total LDL 
concentration.29 
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 Triglycerides are also associated with increased concentration 
of important procoagulant factors such as plasminogen activator 
inhibitor- 1. Thus elevated triglyceride levels directly influence the 
thrombus formation. 
 
Non-HDL cholesterol (Total cholesterol- HDL cholesterol) is a 
secondary goal of therapy in patients with triglycerides > 200 mg/dl 
and therapeutic cutoff point for non-HDL cholesterol are 30mg/dl 
more than for LDL cholesterol.  
.   
METABOLIC SYNDROME AND HYPERTENSION 
 
The relation between insulin resistance and hypertension is well 
established,30 And relates to several different mechanisms. First, it is 
important to note that insulin is a vasodilator when given intravenously 
to people of normal weight,31 with secondary effects on sodium 
reabsorption in the kidney.32 Evidence indicates that sodium 
reabsorption is increased in white people but not Africans or Asians 
with the metabolic syndrome.33 In the setting of insulin resistance, the 
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vasodilator effect of insulin can be lost, 34 but the renal effect on 
sodium reabsorption preserved.35  
 
Fatty acids themselves can mediate relative vasoconstriction.36 
Insulin also increases the activity of the sympathetic nervous system,37 
an effect that might also be preserved in the setting of the insulin  
resistance.38 However, when assessed by concentration of fasting 
insulin, HOMA or the HOMA insulin resistance index (HOMA-IR),39 
insulin resistance contributes only modestly to the increased 
prevalence of hypertension in the metabolic syndrome.40 When blood 
pressure measures > 130/85 mm Hg, it forms one of the clinical 
diagnostic criteria for metabolic syndrome under NCEP ATP 3 
guidelines. 
 
Metabolic syndrome and obesity  
 
Obesity is an important modifiable risk factor for cardiovascular 
disease, including diabetes type 2, hypertension, hypercholesterolemia, 
coronary heart disease, and stroke.41 The rising prevalence of type 2 
diabetes, and metabolic syndrome in the developing countries, appears 
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to be mainly related to the increasing number of overweight and obese 
individual all over the world.42 Accordingly, both World Health 
Organization and the National Heart, Lung and Blood Institute has 
defined obesity as a body mass index of more than 30 kg/ m2 and BMI 
value between 25 and 30 is defined as over weight or pre obese.  
 
Classification of overweight in Adults (WHO)  
 
Classification BMI Risk of co-
morbidities 
Asia Pacific 
Guidelines 
Underweight < 18.5 low < 18.5 
Normal range 18.5- 24.9 average 18.5- 23 
Overweight > 25   
   Pre-obese 25- 29.9 increased 23-24.9 
   Obese class 1 30- 34.9 moderate 25- 30 
   Obese class 2 35-39.9 severe > 30 
   Obese class 3 > 40   
 
Obesity is defined as the presence of abnormally large amount of 
adipose tissue.  
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Measurement of adipose tissue is done by clinically as follows 43 
 
1.   BMI: It is a measure of the ratio between weight (kg) and height 
(m2). It clearly relates body fat independent of height. The only 
pitfall in BMI calculation, that it does not take musculature and 
differential adipose tissue into account. 
 
2. Skin-fold thickness: It is used to measure fat distribution. 
Disadvantages are observer’s error and failure to accommodate 
the fat contour. 
 
3. Measurement of body circumference: Waist- hip ratio higher than 
0.72 are abnormal. The only pitfall is to evolve standards for a 
particular ethnic group. 
 
4.   Waist circumference: It is used to identify body weight component 
of metabolic syndrome. It is measured at 1 cm above navel at 
minimal respiration. Waist circumference greater than 102 cm for 
male and greater than 88 cm for female is used as one of clinical 
diagnosing criteria for metabolic syndrome. 
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5. Because ATP 3 criteria for Waist circumference might not be     
appropriate for Asian population, the cutoff value for metabolic 
syndrome is changed to more than 90 cm for men and more than 80 
cm for women.44 
                
For several definition of the metabolic syndrome, waist 
circumference is included. Mechanistically, a distinction between a 
large waist due to increases in subcutaneous adipose tissue versus 
visceral fat is debated. This distinction can be made with computed 
tomography or magnetic resonance imaging.45  
 
With increases in intra-abdominal or visceral adipose tissue, a 
higher rate of flux of adipose tissue-derived free fatty acids to the liver 
through the splanchnic circulation would be expected, whereas 
increases in abdominal subcutaneous fat would release lipolysis 
products into the systemic circulation and avoid more direct effects on 
hepatic metabolism (i.e., glucose production, lipid synthesis, and 
secretion of prothrombotic proteins such as fibrinogen and 
plasminogen activator inhibitor 1).46  
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Despite these potential differences in mechanisms related to 
excessive abdominal adipose tissue distribution, the clinical diagnosis 
of the metabolic syndrome does not distinguish between increases in 
subcutaneous and visceral fat.  
 
Yet, perhaps by a mechanism related to free fatty acid flux and 
metabolism, the relative predominance of visceral rather than   
subcutaneous adipose tissue with increasing waist circumference in 
Asians and Asian Indians47 renders the relative prevalence of the 
syndrome higher than in African- American men in whom 
subcutaneous fat predominates.48  
 
However, there is evidence that the elevated postprandial free 
fatty acid release in upper body obese women originates from the non- 
splanchnic upper body fat, and not from the visceral depot.49 These 
results suggest that visceral fat might be a marker for, but not the 
source of, excess postprandial free fatty acids in obesity. 
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VASCULAR ENDOTHLIAL DYSFUNCTION  
 
Endothelial dysfunction occurs very early in the process of 
atherogenesis, which impairs normal vasodilator response. Endothelial 
dysfunction is therefore an important factor not only in atherosclerosis 
but also in hypertensive heart disease; Dysfunction allows platelets to 
adhere to the vessel wall and in turn causes contraction by thromboxane 
A2 and serotonin. Platelet-derived growth factor induces migration of 
smooth muscle cells. Endothelial cells produce growth promoters and 
inhibitors. The balance between them is maintained in normal endothelial 
function, under conditions of dysfunction the smooth muscle cells 
proliferate and migrate.50  
 
Some vascular trees are more prone to the development of 
endothelial dysfunction like coronary arteries and aorta branches while 
some are relatively protected like the internal mammary artery and the 
brachial artery. The recognized known cardiac risk factors including age, 
gender, hypertension, hyperlipidaemia, diabetes mellitus, smoking, 
mental stress, and hyperhomocysteinaemia have been associated with 
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endothelial dysfunction. Some of the above mentioned risk factors are 
component of metabolic syndrome.  
 
It is well known endothelial dysfunction can be detected well 
before the development of angiographically significant atherosclerotic 
plaque.51 Abnormalities in peripheral endothelial function correlate with 
the presence of coronary vasomotor dysfunction.  
 
The correlation in endothelial function in both the coronary and the 
peripheral vasculature suggests that a common pathway contributed to 
endothelial dysfunction in both vascular beds.52 
 
METABOLIC SYNDROME AND CORONARY ARTERY DISEASE  
 
The twin epidemics of diabetes mellitus and heart disease are a 
major threat to the well-being as. It is believed that a combination of 
factors, genetic and environmental including newer risk factors like the 
metabolic syndrome and hypercoagulability in addition to traditional risk 
factors like smoking, hypertension and hypercholesterolemia is the 
culprit behind the explosive rise in the incidence of these diseases. CAD 
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in DM is not only 2-4 times more frequent than non-diabetics and also 
has a worse prognosis.  
 
Many patients have sub clinical or asymptomatic CAD which can    
have   devastating consequences. Tight glycaemic control alone only has 
a marginal effect in controlling CAD. This can be treated by a 
multifactorial approach which includes not only adequate glycaemic 
control but also control of dyslipidemia, hypertension which form part of 
metabolic syndrome.53 
       
The unprecedented increase in diabetes and cardiovascular disease 
(CVD) prevalence is evident from the report of WHO which shows that 
India tops the world with the largest number of subjects. According to 
recent WHO reports presently India has 32 million diabetic subjects    
and this is projected to increase to 100 million i.e. a rise by 250 % by the 
year 2035; in addition there is also a growing incidence of metabolic 
syndrome. This syndrome is a deadly combination of hypertension, 
diabetes mellitus, and dyslipidemia with abdominal obesity and often 
leads to heart disease.  
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The cause of this is both bad genes and defective environmental 
influences. Hence, in the coming decades the burden of CVD related to 
DM will increase significantly. Most diabetic’s die of CVD and 
atherosclerosis accounts for almost 80% of all diabetic mortality.54 
Presence of DM increases the risk of cardiovascular disease (CVD) 2-4 
folds. Type 2 DM represents more than 90% of the diabetic population. 
However type 1 DM also have an independently higher risk of CVD and 
their disease develops at younger age.  
   
All the manifestations of CAD are at least two-fold more common 
in patients with DM than in nondiabetic individuals. Conversely, the 
prevalence of DM in CAD is approximately 20%.55 There is evidence 
from Indian data as well that CAD is more common in diabetic subjects. 
Studies conducted in south India by Mohan et al and Ramchandran et al 
in Chennai showed a prevalence of diabetes varying from 12-16%. 
        
In a study done at MV Diabetes Centre, Madras; the prevalence of 
CAD was assessed in a large cohort of 6597 NIDDM patients.56 Overall 
17.8% of patients had CAD. Its prevalence was not significantly different 
in males and females, The Chennai Urban Population Study (CUPS) 
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reported that overall CAD prevalence was 11%. 12% of this population 
was diabetic. Among these 21.4% had CAD, more than the double that of 
non-diabetics. All these data suggest that the epidemic of type 2 DM and 
CAD has already assumed alarming proportions.  
 
Cardiovascular risk factors 
 
Diabetes mellitus and coronary artery disease share many common 
risk factors. According to Reaven, diabetes and CAD are constituents 
of the metabolic syndrome in which insulin resistance plays a 
contributory role. There is a clustering of several metabolic disorders 
like dyslipidemia, HTN, hyperglycemia and central abdominal obesity.  
 
In addition, a number of other risk factors for CAD such as 
atherothrombotic factors, fibrinolytic factors, coagulation factors 
inflammatory markers have also been described in diabetic patients.  
 
Risk factors more common in Asians 
1. Decreased physical activity  
2. Increased central obesity 
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3. Hyperinsulinemia and increased insulin resistance  
4. Decreased beta cell function  
5. Increased prevalence of NIDDM  
6. Increased lipoprotein (a)  
7. Increased TG  
8. Decreased HDL 
 
The metabolic syndrome is a constellation of abnormalities 
including glucose intolerance, hyperinsulinemia, dyslipidemia, obesity 
[central or generalized], hypertension and Microalbuminuria, often 
combined with haemostatic and fibrinolytic abnormalities.  
 
The WHO definition of this syndrome includes 57  
1. Impaired glucose regulation or diabetes  
2. Insulin resistance  
3. Raised arterial pressure > 160/90 
4. Raised plasma triglyceride > 150 mg/dl and/or low HDL  
Cholesterol <35 mg/dl in men and <39 mg/dl in women.  
5. Central obesity (males waist to hip ratio > 0.9 females waist to  
hip ratio > 0.85) and / or BMI / 30 kg/m2  
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6. Microalbuminuria 
   
To satisfy the criterion of metabolic syndrome a patient needed to 
have either criterion (1) or (2) positive along with at least 2 of the 4 
remaining criteria.  
 
Two major studies on the metabolic syndrome include a recent 
population-based study by Isomaa and Coworkers in Finland and Sweden 
concluded that the metabolic syndrome was present in 10% of subjects 
with normal glucose tolerance, 50% of subjects with impaired fasting 
glucose or impaired glucose tolerance and 80% of subjects with type 2 
diabetes. The risk of coronary artery disease and stroke was markedly 
increased (nearly three-fold) in those with the syndrome. 
 
It is clear that an excess of established risk factors for heart disease 
in not the only explanation for the increased CAD among Asians. 
Perhaps a constellation of cardiovascular risk factors typical of these 
observed in insulin resistant status operates in Indians; notably increased 
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triglycerides, decreased HDL, hyperinsulinemia, central obesity and a 
high prevalence of type 2 diabetes (as part of the metabolic syndrome or 
independently).  
 
Recent findings suggest that part of this risk is inherited, probably 
linked to lipoprotein (a) and genetic polymorphism. This when combined 
with environmental influence of westernization including obesity, 
decreased physical activity, dietary changes, increased LDL cholesterol 
and diabetes can be transformed into very potent risk factor for IHD. This 
may be mediated through an increased thrombotic tendency related to 
increased plasminogen activator inhibitor-1 (PAl-1) and reduced tissue 
plasminogen levels. 
 
Treadmill test is most widely used for both diagnosing ischemic 
heart disease and as well as estimating their prognosis by using 12 lead 
electrocardiography. It predicts the likelihood of coronary artery disease 
in 98% of persons with typical angina. The positive response to ischemia 
is flat ST segment depression of >0.1mV below baseline (PR segment) 
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last longer than 0.08s. Negative test does not exclude the coronary artery 
disease although it makes the three-vessel (or) left main coronary artery 
disease unlikely.   
 
 
METABOLIC SYNDROME AND STROKE 
 
Stroke is the second leading cause of death worldwide.58 In India 
community surveys have shown a crude prevalence rate for hemiplegia in 
range of 200 per 100000 persons nearly 1.5% of all medical and around 
20% of neurological cases.59 In India, peak year of occurrence of stroke 
between 55-65 years.60 
 
Risk factors for stroke 
1. Systemic arterial hypertension 
        2.  Diabetes  
 3.  Hyperlipidaemia (particularly, low HDL and high LDL) 
 4.  Smoking 
 5.  Older age 
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6. Family history of thrombotic stroke are proven atherosclerosis          
risk factors for ischemic stroke 
 
 
Of these above mentioned risk factors, first three forms the 
components of the metabolic syndrome. Among this hypertension is the 
most significant risk factor for ischemic stoke.61 So all hypertensive 
patients to be treated. Whether or not tight control of blood sugar in 
patients with diabetes lowers stroke risk is uncertain.62  
 
 
But one Meta analysis of incidence of stroke in Asian population 
showed a positive relation between increasing cholesterol levels and non- 
hemorrhagic stroke63 and several trials have confirmed that statin drugs 
reduce the risk of stroke even in patients without elevated LDL or low 
HDL.64  
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PERIPHERAL ARTERIAL DISEASE 
 
 The term peripheral arterial disease generally refers to atherosclerosis 
when it obstructs the blood supply to the lower or upper extremities. It is 
an important manifestation of systemic atherosclerosis, and is a strong 
marker for risk of major cardiovascular and cerebrovascular events,  
      
 
  The risk factor most correlated with the onset and progression of 
peripheral arterial disease is cigarette smoking, followed by diabetes 
mellitus. Abnormalities in lipid metabolism are also associated with an 
increased prevalence of peripheral arterial disease; Relative risk for 
peripheral arterial disease is about 1.1 for each 10 mg /dl increase in total 
cholesterol with similar increases for development of claudication.65 
 
Peripheral Vascular Disease of the lower extremity is an important cause 
of morbidity and affects 10 million people in India.66 
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Unique Features of Peripheral Vascular Disease in Indians 
  
 
1. Presentation at younger age (mean age 45 years) 
  
2. Increased association of diabetes and presence of typical  
 
 Diabetic Peripheral Vascular Disease  
3. Strongest correlation with presence of Coronary Artery Disease  
     (CAD) and Cerebrovascular Disease (CVD). 
 
Peripheral vascular disease in diabetes 
Diabetes Mellitus is an important risk factor of lower extremity 
arterial disease (LEAD) in India. Smoking and insulin resistance are 
frequently present in patients with diabetes and contribute an additional 
risk for vascular disease.  
In population based and epidemiology based studies, 67 It is 
estimated that 20-30% of diabetic patients over 65 years of age have 
peripheral arterial disease. In 75% cases peripheral vascular disease is 
asymptomatic, in 25% cases peripheral vascular disease is symptomatic 
with intermittent claudication, coldness and numbness of feet, weakness 
of lower limb, dependent rubor, non healing ulcer and gangrene.  
  38 
Clinical presentation of lower limb vascular disorders  
1. Intermittent Claudication  
It is characterized by pain or fatigue in the affected leg on walking 
and relieved by rest. It occurs when the oxygen demand of the skeletal 
muscle exceeds the blood supply during exercise and is due to activation 
of local receptors by accumulated lactic acid. Claudication has been 
graded using different classifications. The commonly used classification 
is  
Fontaine classification 68 
Stage            Symptoms  
  I                   Asymptomatic  
 II                   Intermittent claudication  
 II a                Pain free, claudication on walking > 200 meters  
 II b                Pain free, claudication on walking < 200 meters  
 III                  Rest and nocturnal pain  
 IV                  Necrosis, gangrene  
2. Rest Pain  
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Clinical Methods  
 
1. Palpation of peripheral pulses  
Absence of peripheral pulses is an important finding. Absent 
posterior tibial, popliteal or femoral pulses with / without bruits indicate 
significant occlusive peripheral vascular diseases especially if associated 
with symptoms like claudication. Physical examination often reveals 
decreased pulsations. Capillary refilling, increased venous filling time 
(>20 seconds), atrophic changes, loss of hair, discoloration of skin and 
decreased temperature are common clinical findings. 
 
2. Ankle brachial index 
It is the ratio of the systolic blood pressure measurement of the 
ankle to that of the brachial artery.  
a) A normal ABI should be less or equal to 1.1  
b) An index of < 0.9 is abnormal and indicates occlusive PVD, especially 
in presence of absent peripheral pulses.  
c) ABI less than or equal to 0.8 indicates PVD regardless of symptoms. 
d)  Because of the presence of calcific medial sclerosis which prevents 
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the compression of the calcified vessel, diabetics present a challenge to 
the sensitivity of this method. 
  
Duplex Imaging 
 Gray scale and color flow imaging are useful in localizing the 
diseased segment while spectral imaging is used to assess the severity of 
the lesion. A two fold or greater increase in peak systolic velocity at the 
site of stenosis indicates 50% or more stenosis. Doppler signals are 
absent if artery is totally occluded.   
  
 
 
 
 
 
 
  41 
 
MATERIALS AND METHODS 
 
A sample of 120 cases of elderly (60 years & above) men and 
women were selected by systematic sampling methods from our medical 
out patients department, Government General Hospital, 20 cases were 
excluded since they had hemorrhagic stroke and selected cases were 
analyzed for the presence of metabolic syndrome and vascular 
complications present in that group.  
 
The patients having three or more of the following criteria 
(according to the National Cholesterol Education Guidelines Adult 
Treatment Panel (ATP) 3 report) were defined as having the metabolic 
syndrome: 
   1. Waist circumference > 102 cm in men and > 88 cm in women 
   2. Hypertriglyceridemia: ≥ 150 mg/dl (≥ 1.7 mmol/l). 
   3. Low HDL: < 40 mg/dl in men (<1.0 mmol/l)  
              and   < 50 mg/dl in women (<1.3 mmol/l)  
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5. High blood pressure: ≥ 130/85 mmHg or use of antihypertensive  
medication.  
6. High fasting plasma venous glucose: ≥ 110 mg/dl (≥ 6.1 mmol/l) or  
treatment for diabetes. 
 
Because the ATP 3 criteria for HDL cholesterol and waist 
circumference might not be appropriate for Asian population, additional 
calculations for the prevalence of the metabolic syndrome were done 
based on a recommended regional cutoff for HDL cholesterol of less than 
40 mg/dl (1.0 mmol/l) for both men and women and waist circumference 
greater than 90 cm for men and greater than 80 cm for women.69 
 
The 1997 American Diabetes Association criteria were used to 
define diabetes.70 we considered a subject to have diabetes when the 
fasting plasma venous glucose was ≥ 126 mg/dl (≥ 7mmol/l) in two 
consecutive assessments or if they were on treatment for diabetes.   
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For each enrolled subject, the personal and family medical 
histories were obtained. On the study day, height and weight were 
measured twice during the examination. Weight was measured to the 
nearest 100 g with bare foot. Height was measured to the nearest mm 
with a stadiometer. Body mass index (BMI) was calculated by the 
formula   
  
BMI = Weight (kg) / Height (m) 2  
 
Overweight was defined as a BMI of 23 kg/m2 or greater, 
according to Asia Pacific guidelines.  Blood pressure was measured was 
measured with patient in the sitting position after a 5 min rest, with 
mercury sphygmomanometer (cuff size 12.5 × 40 cm). The systolic BP 
and diastolic BP were read to the nearest 2 mmHg. Disappearance of 
Korotkoff’s sounds (phase 5) was the criterion for diastolic BP.  Standard 
12 lead ECG was obtained from each patients. Echocardiogram was 
obtained for each patient to show the features of ischemia changes. Waist 
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circumference was measured at 1 cm above the navel at minimal 
respiration.71 
 
The definition of vascular disease included coronary heart disease, 
stroke, and/ or peripheral arterial disease. The presence of vascular 
disease was established based on physical examination and personal 
medical history. Prevalent coronary heart disease was diagnosed by the 
presence of history of hospitalization for myocardial infarction, coronary 
bypass artery grafting, or percutaneous transluminal angioplasty, or by 
the presence of stable angina, positive exercise tolerance test (The 
development of 0.10 mV (1 mm) or greater of J point depression 
measured from PQ segment with a flat ST segment depression of 0.10 
mV or greater at 80 m sec after J point in three consequent beats is the 
evidence of ischemia) or coronary angiography with at least one 
substantial coronary artery stenosis.  
 
Subjects were considered to have a stroke if they had been 
discharged from a hospital with this diagnosis. Only those with 
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confirmation of a non-hemorrhagic stroke by a CT scan were included.  
Peripheral arterial disease was established by physical examination and 
the presence of intermittent claudication, and Duplex imaging. If a 
subject had more than one vascular disease manifestation he/she was 
considered only once (adjustment for overlap).   
  
The study groups were classified into four groups i.e.) metabolic 
syndrome with diabetes, metabolic syndrome without diabetes, no 
metabolic syndrome with diabetes, no metabolic syndrome without 
diabetes. Initially prevalence of metabolic syndrome in the study group 
was assessed, and then vascular disease prevalence was assessed by 
comparing with non-metabolic syndrome group. 
 
STUDY DESIGN: 
To evaluate the presence of metabolic syndrome and assess the 
prevalence of vascular diseases in elderly with the metabolic syndrome 
with or without diabetes when compared with subjects without metabolic 
syndrome, a cross-sectional study design was chosen. 
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Laboratory methods  
  Overnight fasting (at least 10 hours) blood specimen were obtained 
for measurement of serum lipids and plasma glucose. Concentration of 
total cholesterol, HDL- cholesterol, and triglycerides were assessed 
enzymatically with commercially available reagents. Concentration of 
LDL- cholesterol was calculated by use of the Friedewald equation for 
participants who had triglycerides (< 400 mg/dl) 
 
LDL = TC – HDL-c – TGL/5 
 
Serum creatinine, blood urea, serum electrolytes, and other biochemical 
evaluation were performed according to routine standards, at biochemical 
lab attached to Institute of Biochemistry, Govt. General Hospital. 
 
 
  47 
STATISTICAL ANALYSIS 
 
Statistical analysis was carried out for 100 subjects [45 metabolic 
syndrome, 55 no metabolic syndrome] after categorizing each variable. 
Base line data was collected from patients with vascular disease and 
metabolic syndrome and without metabolic syndrome. Age, sex, lipid 
profile, non HDL cholesterol, components of the metabolic syndrome 
such as waist circumference, systemic BP > 130/85, fasting glucose > 
110, Triglycerides >150, Low HDL < 40 mg/dl were analyzed. 
 
The significance of difference in means between two groups and 
the significance of difference in proportions were analyzed by Z test. The 
prevalence of vascular disease in the metabolic syndrome were analyzed 
and compared with non-metabolic syndrome group. Statistical 
significance was taken when two-sided p value < 0.05. Statistical analysis 
was carried out using standard formulae by Microsoft Excel 2003. The 
correlation between metabolic syndrome components and vascular 
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Observations 
Table 1 
Prevalence of vascular diseases in Total met syn group 
 
 
 
All 
Subjects Met syn all 
No Met syn 
all P value 
 n =100 n = 45 n = 55  
Male           (%) 56 51.1 60.0 0.368 
WC             (%) 52 86.7 23.6 <0.00001 
 High FGL   (%) 44 68.9 23.6 <0.00001 
  AH            (%) 47 75.6 23.6 <0.00001 
 High TGL   (%) 47 91.1 10.9 <0.00001 
  Low HDL   (%) 44 66.7 25.5 <0.00001 
 DM            (%) 34 53.3 18.2 <0.00001 
CHD           (%) 31 55.6 10.9 <0.00001 
Stroke       (%) 25 44.4 9.1 <0.00001 
PAD          (%) 2 4.4 0.0 0.161 
Vas D        (%) 42 71.1 18.2 <0.00001 
Vas D > 1 (%) 16 33.3 1.8 <0.00001 
 
WC- waist circumference; AH- arterial hypertension  
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Table 2 
                Prevalence of vascular diseases in met syn with DM group 
 
 All Subject Met syn + DM No Met syn +DM P value 
 n =100 n = 24 n = 10  
CHD          (%) 31 66.7 30.0 <0.034 
Stroke       (%) 25 58.3 30.0 <0.108 
PAD          (%) 2 4.2 0.0 <0.316 
Vas D        (%) 42 87.5 50.0 <0.026 
Vas D > 1 (%) 16 41.7 10.0 <0.020 
  
 
Table 3 
              Prevalence of vascular diseases in met syn without DM group 
 
 All Subject Met syn +no DM No Met syn + No DM P value 
 n =100 n = 21 n = 45  
CHD          (%) 31 42.9 6.7 <0.0006 
Stroke       (%) 25 28.6 4.4 <0.0124 
PAD          (%) 2 4.8 0.0 <0.270 
Vas D        (%) 42 52.4 11.1 <0.0002 
Vas D > 1 (%) 16 23.8 0.0 <0.006 
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                                                     Table 4 
Lipid profile in met syn and no met syn group 
 
Lipid fraction Met syn No met syn P value 
Total cholesterol 214.07± 18.24 195.09± 11.19 <0.0001 
HDL 39.27± 4.29 42.05± 4.13 <0.0008 
Triglycerides 177.53± 22.89 147.47± 11.77 <0.0001 
LDL 139.29± 17.82 123.54± 13.63 <0.0001 
 
 
The prevalence of metabolic syndrome in our study group was 
45%. The prevalence of metabolic syndrome in men was 51.1%. The 
prevalence of metabolic syndrome in women was 48.9%. Both genders 
had same prevalence of metabolic syndrome (p = 0.5) and was not 
statistically significant.  
 
The overlap adjusted prevalence of vascular disease in all 
participants was 42%. All subjects with the metabolic syndrome (n 
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=45) had a vascular disease prevalence of 71.1%, significantly higher 
than that of people (n = 55) without metabolic syndrome (18.2%, p < 
0.0001). 
 
Participants without both the metabolic syndrome and DM (n = 
45) had the lowest vascular disease prevalence (11.1%), while subjects 
with DM but without the metabolic syndrome (n = 10) had a vascular 
disease prevalence of 50% (p < 0.05). This was nearly similar to that 
of people (n = 21) with the metabolic syndrome without DM (52.4%), 
but significantly lower than that of participants (n = 24) with both the 
metabolic syndrome and DM (87.5%, p < 0.05).  
 
The concomitant presence of CHD, stroke and PAD in the 
metabolic syndrome group, with or without DM, (33.3%) was higher 
than in those without the metabolic syndrome (1.8%). Thus, the sum 
total of CHD, stroke and PAD was higher in the metabolic syndrome 
group than in those without the metabolic syndrome. In the metabolic 
syndrome group, having more than one of CHD, stroke or PAD, the 
prevalence of vascular disease, when counted as a presence of CHD, 
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stroke and/or PAD was 71.1%. In contrast, this figure was 18.2% for 
those without the metabolic syndrome.  
 
All the lipid values of subjects with the metabolic syndrome 
were significantly different from those of subjects without the 
metabolic syndrome. A substantial percentage (71.1%) of patients with 
the metabolic syndrome had high LDL-C levels > 130 mg/dl (> 3.4 
mmol/l) and even more (82.2%) had a non- HDL-C > 160mg/dl (> 
4.1mmol/l). 
 
The prevalence of vascular disease in the metabolic syndrome 
group was 71.1%. Among the vascular diseases coronary artery disease 
had the highest prevalence; PAD had least prevalence and stroke 
prevalence in between. 
 
Among the component factors of metabolic syndrome, waist 
circumference (> 90 cm in male, >80 cm in female) had the highest 
prevalence than other factors. Highest BMI was prevalent in the 
metabolic syndrome with diabetes group. 
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The prevalence of vascular disease in the metabolic syndrome 
alone group without diabetes was significantly (p <0.0002) higher than 
that of group without metabolic syndrome and no DM but similar to 
that of group without metabolic syndrome and with DM. Thus the 
presence of metabolic syndrome alone without DM has increased the 
risk of developing vascular diseases. 
  
We assessed the strength of correlation of the metabolic 
syndrome components with the vascular diseases. We found that waist 
circumference, fasting glucose, triglyceride, arterial hypertension were 
positively correlating with vascular events, and HDL was inversely 
correlated with vascular events. Arterial hypertension strongly 
correlated with stroke, TGL strongly correlated with CHD and HDL 
was inversely correlated with both CHD and stroke. 
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Prevalence of diabetes 
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Fig. 3 
 
Prevalence of Central obesity 
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Fig. 4 
 
Prevalence of obesity (BMI >23) 
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Fig. 5 
 
Prevalence of High triglyceride 
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Fig. 6 
 
Prevalence of Low HDL 
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Fig. 7   
 
Prevalence of systemic hypertension 
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Fig. 8 
 
Prevalence of vascular diseases  
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Fig. 9 
 
Prevalence of CHD  
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Fig. 10 
 
Prevalence of Stroke 
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Fig. 11 
 
Prevalence of Peripheral arterial disease (PAD) 
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Fig. 12 
 
Prevalence of more than 1 vascular disease 
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Fig. 13 
 
                        Prevalence of LDL more than 130 mg/dl  
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Fig. 14 
 
Prevalence of CHD and Stroke in metsyn with DM and No DM 
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Fig. 15 
 
Correlation of vascular events with MetSyn components 
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AH-Arterial hypertension 
FGL- Fasting glucose 
TGL- Triglycerides 
HDL- High density lipoprotein 
WC- Waist circumference 
PAD- Peripheral arterial disease 
CHD- coronary artery disease 
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DISCUSSION 
            
Our results suggest that in our study population, the metabolic 
syndrome prevalence in the elderly was 45%; in contrast with the 
population (adult) based METS-GREECE Multicenter study which had 
a prevalence of 23.6%. This was due to the clustering of the metabolic 
syndrome in the elderly group and increasing prevalence of metabolic 
syndrome with age.  In accordance with METS-GREECE Multicenter 
study, our study identifies a substantial additional vascular risk 
(CHD/stroke/PAD) in men and women, even in those without diabetes.  
 
Furthermore, the overlap adjusted prevalent vascular disease in 
those with the metabolic syndrome but no diabetes were significantly 
greater than that of those in the non-metabolic syndrome group, 
underlining the high risk associated with the Metsyn. These findings in 
accordance with METS-GREECE Multicenter study, suggest that the 
metabolic syndrome should probably be added to the list of coronary 
heart disease equivalents, even in the absence of diabetes. 
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The prevalence of increased vascular disease in subjects with the 
metabolic syndrome may be explained by the components that define 
the metabolic syndrome in association with other, not routinely 
measured factors. For example, impaired fibrinolysis, oxidative stress 
hypercoagulability, high LDL-C levels, increased small dense LDL 
particles, inflammation and hyperinsulinemia. It was also reported that 
the Metsyn is associated with higher levels of oxidized LDL-C, 
apolipoprotein-B, urate, leptin, fibrinogen, leucocytes, erythrocyte 
sedimentation rate and soluble endothelial adhesion molecule and 
lower apolipoprotein-A concentrations.  
 
Apart from the five components of the metabolic syndrome, 
other two factors play an important role for coronary heart disease risk. 
This was partly due to increased levels of LDL-C, small dense LDL 
particles and elevated non-HDL cholesterol. All these parameters 
cannot be assessed in each patient in everyday clinical practice. 
However, LDL-C and non-HDL-C (total cholesterol minus HDL-C) 
are easily calculated. 
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Although LDL-C is not considered as a component of the 
metabolic syndrome, many of patients have raised levels of LDL-C. In 
our study, 71.1% of the subjects with the metabolic syndrome had a 
LDL-C > 130 mg/dl (> 3.4 mmol/l), this finding more in accordance 
with METS-GREECE Multicenter study which had 64% of the 
subjects with LDL-C > 130 mg/dl and the importance of LDL-C is that 
it forms primary treatment target in the management of dyslipidemia.  
 
The contribution of high LDL-C levels to vascular disease risk 
in subjects with the Metsyn was highlighted by retrospective analysis 
of the landmark statin trails. The placebo data from the Scandinavian 
Simvastatin Survival Study (4s) and the Air Force/Texas Coronary 
Atherosclerosis Prevention Study (AFCAPS/Tex-CAPS) showed that 
the relative risk of major coronary events associated with the 
metabolic syndrome, after excluding DM was 1.5 (95% CI = 1.2-1.8) 
and 1.4  (95% CI = 1.04-1.9) respectively, in comparison to subjects 
without the metabolic syndrome.  
 
These data demonstrate that the metabolic syndrome is 
associated with an increased vascular risk in hypercholesterolemic 
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patients with CHD in 4s and in those with average LDL-C levels and 
low HDL-C but without CHD in AFCAPS/TexCAPS. This argues for 
whether elevated LDL-C might be considered modifying components 
of the metabolic syndrome, especially in the presence of elevated 
triglycerides (indicating small dense LDL particles with increased 
atherogenicity). 
 
In individuals with triglycerides >200 mg/dl (> 2.3 mmol/l), 
probably the majority of subjects with the metabolic syndrome, non-
HDL is a secondary treatment target. Non-HDL-C includes cholesterol 
in LDL and triglyceride-rich lipoproteins. In our study, 82.2% of 
subjects with the metabolic syndrome had a non-HDL-C level >160 
mg/dl (>4.1 mmol/l), in accordance with METS-GREECE Multicenter 
study which had 69% of subjects with non-HDL-C level >160 mg/dl. 
 
In the Lipid Research Clinics follow-up study, non-HDL-C level 
was a better predictor of CHD death than LDL-C. In the GREACE 
study, non-HDL-C level was a better predictor of risk for clinical 
vascular events in untreated patients than LDL-C, in these instances 
non-HDL-C should be the primary treatment target. Therefore, non-
  58
HDL-C may be incorporated in the definition of the metabolic 
syndrome. 
 
Several studies including METS-GREECE Multicenter study 
and data from our study group suggest that the metabolic syndrome, 
even in the absence of diabetes, is associated with an increased 
vascular risk. This will reset the LDL-C and non-HDL-C treatment 
targets and may result in additional clinical benefit in these subjects. 
 
Study limitations 
         
 The study is a hospital based study and may not be 
representative of general population. As a cross-sectional study, the 
present analysis is limited in its ability to elucidate causal relationships 
between risk factors and outcome. Some subgroups like no Metsyn but 
with diabetes are small in number. 
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CONCLUSIONS 
 
1.  The prevalence of metabolic syndrome in our study group was 
45% and vascular disease (coronary artery disease/stroke) 
prevalence was markedly increased in the presence of the 
metabolic syndrome in the elderly. 
 
2.  Those with both the metabolic syndrome and diabetes had the 
highest prevalence of coronary artery disease and stroke, 
followed by those with the metabolic syndrome but without 
diabetes in the elderly. 
 
3.  The metabolic syndrome is significantly associated with vascular 
disease risk, even in the absence of diabetes in the elderly; 
probably metabolic syndrome alone without diabetes can be 
considered as a coronary heart disease-risk equivalent in future 
guidelines. 
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4.    Among metabolic syndrome components,   Arterial hypertension 
strongly correlated with stroke, Triglycerides strongly correlated 
with coronary artery disease and High density lipoprotein was 
inversely correlated with both coronary artery disease and 
stroke. 
 
5.  Both raised levels of low density lipoprotein and non-high 
density lipoprotein (not a component of metabolic syndrome) are 
strongly correlated with coronary artery disease in the metabolic 
syndrome group, and hence these can be considered as 
modifying components of metabolic syndrome 
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SCOPE FOR FUTURE STUDIES 
 
This study conducted in our Indian population has significant 
observation and had potential therapeutic implications. Our study 
concluded that Met syn without DM can be considered as a coronary 
heart disease-risk equivalent in future guidelines. This initiative would 
reset treatment targets and whether it potentially provides additional 
benefit in patients with the Met syndrome, which can be elucidated by 
further studies. 
  
In Met syn group, majority of patients had elevated lipid values.  
We can asses the effectiveness of hypolipidemic drug therapy in this 
Met syn group and can elucidate whether Met syn is also a major 
factor in response to therapy, like it influences the risk of CHD by 
further future studies. 
  
PROFORMA 
Name:  
Age:  
Sex: 
Occupation: 
OP No: 
Address: 
DM   Y/N 
Hypertension Y/N 
Drugs used  
H/o hospitalization for Myocardial infarction  
H/o stable angina  
H/o coronary bypass artery grafting 
H/o percutaneous transluminal angioplasty 
H/o cerebrovascular accident 
H/o intermittent claudication  
Co morbid condition:  
Smoker: Type/ quantity/ duration 
Alcohol: Type/ quantity/ duration 
Family H/o DM/HT/ CAD/ CVA 
  
Examination 
   Height           weight        BMI        waist circumference  
   Pulse             peripheral pulses        carotids Equal/unequal 
   BP (upper limb) 
    CVS              RS            Abd            CNS 
INVESTIGATIONS 
            Blood glucose- Fasting                           postprandial 
            Urine     Alb              sugar             deposit  
            Lipid profile 
                         TC                 TGL               HDL             LDL       
            ECG 
            ECHO 
            CT Brain 
    Stress ECG 
    Coronary angiography 
    Duplex imaging 
Inclusion criteria 
       1. Age ≥ 60 yr (both sexes) 
Exclusion criteria 
       1. Hemorrhagic stroke (on CT brain) 
  
 
S.No Name Age Sex Height Weight BMI AH SBP DBP FGL TC TGL HDL LDL non HDL WC DM CHD Stroke PAD 
1 alagami 65 f 155 60 24.97 y 150 80 130 200 168 45 121 155 78 y n n n 
2 alagar 62 m 168 78 27.64 n 128 82 132 230 202 33 157 197 93 y y y n 
3 anadi 61 f 165 56 20.57 y 140 100 98 186 158 44 110 142 98 n n n n 
4 anandraj 60 m 167 69 24.74 n 128 82 128 230 204 38 151 192 93 y y n n 
5 devan 69 m 168 68 24.09 y 140 88 98 224 206 34 149 190 91 n y n n 
6 devi 71 f 155 55 22.89 y 132 90 98 186 148 46 110 140 82 n n n n 
7 duraiyammal 62 f 145 46 21.88 y 140 100 88 198 152 47 121 151 69 n n n n 
8 ganapathi 62 m 170 68 23.53 y 140 92 128 230 204 44 145 186 92 y y n n 
9 girigori 75 m 166 70 25.40 y 150 90 140 220 200 38 142 182 92 y y y n 
10 jayaraj 77 m 162 68 25.91 y 160 70 122 230 200 38 152 192 91 y y y n 
11 kali 68 m 162 60 22.86 n 128 70 98 166 168 38 94 128 98 n n n n 
12 kaliyammal 68 f 162 68 25.91 y 140 88 128 208 160 38 138 170 78 y n y n 
13 kanthamal 70 f 152 62 26.84 y 180 100 140 230 202 32 158 198 103 y y y n 
14 samutharapandian 61 m 155 58 24.14 y 170 100 132 220 204 38 141 182 91 y y y n 
15 krisnan 67 m 173 68 22.72 n 130 84 125 192 152 48 114 144 91 y n n n 
16 kumari 66 f 156 58 23.83 n 126 80 130 202 158 41 129 161 82 y n n n 
17 lakshmi devi 62 f 156 58 23.83 n 120 78 120 210 152 42 138 168 88 n n n n 
18 mani 72 m 168 68 24.09 y 140 90 92 220 200 36 144 184 91 n y y n 
19 murugan 68 m 164 62 23.05 y 148 98 92 220 200 38 142 182 92 n y y n 
20 natarajan 62 m 166 76 27.58 y 130 90 116 200 152 42 128 158 108 n n n n 
21 natchiar 60 f 152 55 23.81 n 120 74 132 230 204 38 151 192 86 y y n n 
22 padma 65 f 148 54 24.65 n 128 80 124 214 148 38 146 176 86 y n y n 
23 pappa 60 f 152 52 22.51 n 140 100 114 163 156 48 84 115 93 n n n n 
24 parvatam 67 f 140 58 29.59 y 150 90 120 200 160 39 129 161 85 y n y n 
25 parvathi 61 f 160 62 24.22 y 132 94 102 198 160 37 129 161 84 n n n n 
26 pattu 68 m 168 70 24.80 y 170 100 88 200 160 39 129 161 92 n n y y 
27 periyasamy 60 m 162 62 23.62 y 150 88 62 200 147 39 132 161 92 n n y n 
28 raja 72 m 172 70 23.66 y 150 100 118 230 156 36 163 194 91 n n n n 
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29 ramamoorthy 65 m 179 78 24.34 y 160 100 100 230 198 35 155 195 91 n y n n 
30 raman 68 m 178 74 23.36 y 170 10 96 220 204 38 141 182 92 n y y n 
31 ramathilagam 64 f 155 58 24.14 n 128 82 112 210 178 38 136 172 83 n y n n 
32 ramayi 65 f 152 58 25.10 y 140 100 128 230 168 38 158 192 77 y n y n 
33 ramayiyammal 65 f 158 60 24.03 y 170 100 138 220 202 33 147 187 82 y y y n 
34 sakunthala 60 f 154 63 26.56 y 160 100 140 250 170 40 176 210 94 y y n n 
35 sanmugam 68 m 168 74 26.22 y 138 86 132 220 166 42 145 178 92 y y n n 
36 saraswathi 66 f 158 60 24.03 y 140 90 126 210 148 38 142 172 78 y n y n 
37 saroja 63 f 152 60 25.97 y 140 100 116 220 200 37 143 183 83 y y y n 
38 saroja 65 f 158 60 24.03 y 140 88 112 220 152 35 155 185 92 n y n n 
39 sarojini 75 f 145 50 23.78 y 180 90 112 230 200 32 158 198 83 y y y n 
40 satchu 68 f 151 50 21.93 y 140 70 100 212 152 47 135 165 82 n n n n 
41 sivalingam 73 m 178 80 25.25 y 140 96 120 222 200 34 148 188 92 y y y n 
42 subbu 63 m 168 73 25.86 y 140 80 120 240 204 46 153 194 92 y y n n 
43 stanislaus 70 m 160 50 19.53 y 138 86 92 200 162 39 129 161 92 n y y n 
44 sunder 78 m 178 78 24.62 n 126 80 112 222 204 38 143 184 92 n y n n 
45 sunderajan 78 m 172 78 26.37 y 150 80 126 240 200 43 157 197 96 y y n y 
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S.No Name Age Sex Height Weight BMI AH SBP DBP FGL TC TGL HDL LDL NON-HDL WC DM CHD Stroke PAD 
1 aiagar 70 m 168 62 21.97 y 140 100 100 190 148 32 128 158 80 n n n n 
2 alagarsamy 66 m 165 68 24.98 n 120 80 130 196 135 42 127 154 78 y n n n 
3 andal 68 f 156 58 23.83 n 126 82 100 178 148 42 106 136 87 n n n n 
4 babu 60 m 178 74 23.36 y 140 90 100 190 138 42 120 148 88 n n n n 
5 chandra 66 f 156 54 22.19 n 120 78 110 190 148 42 118 148 78 n n n n 
6 chinnamal 62 f 158 54 21.63 n 124 84 100 194 146 44 121 150 76 n n n n 
7 devaki 70 f 140 45 22.96 n 120 80 112 230 148 38 162 192 75 y n y n 
8 durairaj 60 m 173 70 23.39 y 140 80 77 188 146 32 127 156 89 n n n n 
9 ekambaram 75 m 176 65 20.98 n 130 90 110 181 123 47 109 134 77 n n n n 
10 gopalsamy 70 m 168 72 25.51 n 120 80 150 230 148 32 168 198 87 y y y n 
11 govindan 70 m 168 66 23.38 n 126 82 102 188 146 44 115 144 88 n n n n 
12 hari 72 m 168 66 23.38 n 126 84 102 198 148 44 124 154 88 n n n n 
13 indurani 65 f 152 52 22.51 y 160 100 102 198 148 39 129 159 66 n y n n 
14 iyappan 71 m 168 66 23.38 n 128 84 98 198 148 44 124 154 88 n n n n 
15 jeyachandran 63 m 174 72 23.78 n 120 84 82 200 148 42 128 158 88 n n n n 
16 kandan 70 m 178 72 22.72 n 128 82 100 188 148 44 114 144 88 n n n n 
17 karupu 64 m 167 64 22.95 y 140 100 100 198 148 39 129 159 78 n n y n 
18 kothainayagi 60 f 145 48 22.83 n 130 80 112 192 148 40 122 152 75 n n n n 
19 krisnan 63 m 168 60 21.26 n 118 82 100 190 136 42 121 148 88 n n n n 
20 kumar 66 m 165 65 23.88 n 108 84 92 180 148 42 108 138 89 n n n n 
21 kuppu 75 m 172 64 21.63 n 120 80 100 182 136 44 111 138 86 n n n n 
22 lakshmi 63 f 160 58 22.66 n 126 80 126 200 158 42 126 158 78 y n n n 
23 lakshmiyammal 70 f 150 55 24.44 y 140 90 128 220 148 42 148 178 78 y y n n 
24 murugesan 62 m 172 70 23.66 n 124 80 96 188 140 48 112 140 88 n n n n 
25 muthusamy 70 m 164 60 22.31 n 130 80 94 200 148 48 122 152 89 n n n n 
26 nellamal 62 f 158 59 23.63 n 130 80 90 200 146 32 139 168 85 n y n n 
27 padma 69 f 156 56 23.01 n 120 70 100 198 142 42 128 156 88 n n n n 
28 padmavathi 62 f 158 54 21.63 n 110 80 100 182 148 46 106 136 78 n n n n 
29 palani 60 m 165 55 20.20 n 124 84 88 200 136 45 128 155 89 n n n n 
30 panchanathan 66 m 170 70 24.22 n 120 80 130 222 148 38 154 184 86 y y n n 
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31 pandiyammmal 73 f 158 56 22.43 n 126 80 100 198 146 42 127 156 92 n n n n 
32 parameswari 62 f 160 58 22.66 n 124 84 100 188 140 42 118 146 72 n n n n 
33 perumal 63 m 172 60 20.28 n 110 80 110 179 221 46 89 133 82 n n n n 
34 pitchi 71 m 168 66 23.38 n 128 80 114 192 138 48 116 144 88 n n n n 
35 pitchiyandi 62 m 150 50 22.22 n 106 78 106 196 148 46 120 150 92 n n n n 
36 rajeswari 63 f 143 47 22.98 y 134 84 75 206 148 42 134 164 78 n n n n 
37 ramu 72 m 168 66 23.38 n 120 70 82 200 148 48 122 152 89 n n n n 
38 rani 72 f 156 54 22.19 n 130 78 92 190 152 38 122 152 74 n n n n 
39 rathinam 75 f 144 45 21.70 y 130 86 112 190 148 44 116 146 76 y n n n 
40 ravi 76 m 170 68 23.53 n 130 80 114 200 158 46 122 154 88 y n n n 
41 sangeta 70 f 154 52 21.93 n 130 80 100 188 148 43 115 145 88 n n n n 
42 sankar 65 m 172 70 23.66 n 128 80 92 200 148 42 128 158 94 n n n n 
43 sanmugam 73 m 172 70 23.66 n 128 70 112 179 160 47 100 132 88 n n n n 
44 selvi 63 f 158 53 21.23 n 118 78 96 188 136 44 117 144 88 n n n n 
45 sivaprakasam 60 m 154 56 23.61 n 130 80 96 200 148 38 132 162 98 n y n n 
46 subbu 70 m 160 58 22.66 y 140 90 100 190 148 38 122 152 78 n n n n 
47 sundaran 74 m 176 62 20.02 n 130 80 124 200 148 39 131 161 85 y n y n 
48 sundari 66 f 158 60 24.03 n 120 70 130 200 148 42 128 158 78 y n n n 
49 tamilarasi 71 f 160 58 22.66 y 150 94 88 200 148 42 128 158 78 n n n n 
50 tamilselvi 68 f 155 56 23.31 n 128 82 96 188 154 50 107 138 78 n n n n 
51 vadivelu 66 m 158 58 23.23 y 150 90 102 199 148 38 131 161 88 n n y n 
52 valli 72 f 155 56 23.31 y 138 90 98 196 146 42 125 154 78 n n n n 
53 varatharajan 60 m 162 56 21.34 y 150 90 82 196 148 38 128 158 72 n n n n 
54 velu 60 m 168 66 23.38 n 128 70 96 178 146 42 107 136 88 n n n n 
55 venkat 66 m 166 66 23.95 n 126 80 98 200 146 46 125 154 88 n n n n 
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ABBREVIATIONS 
 
 
 AH      -   Arterial Hypertension 
 BMI    -    Body Mass Index 
 CHD   -    Coronary Heart Disease 
 CAD   -    Coronary Artery Disease 
 DM     -     Diabetes Mellitus 
 DBP    -     Diastolic Blood Pressure 
 FGL    -     Fasting Glucose 
 HDL   -     High Density Lipoprotein 
 LDL   -      Low Density Lipoprotein 
 PAD   -      Peripheral Arterial Disease 
 SBP    -      Systolic Blood Pressure 
 TC      -     Total Cholesterol 
 TGL   -     Triglyceride 
 WC     -     Waist Circumference 
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